Opening soon. Stay in the loop

goodmorrowJoin the opening list

DSIP, explained.

Emideltide, delta sleep-inducing peptide. Research, safety questions, and treatment context.

Updated Clinical review pending · Educational draft

The form

Preparation matters

The routine

No personal schedule is set by this guide.

The evidence

See the evidence and source notes below.

Research, approval and availability are separate questions.

Legal status
Rejected by FDA advisers

FDA advisers voted 7 to 6 against allowing it on July 24, 2026.

At Goodmorrow
Not offered

What it is

Delta sleep-inducing peptide is a nine-amino-acid peptide first isolated in the 1970s and named for its apparent effect on deep sleep.

What the evidence shows

Human studies are old, small and inconsistent. The FDA reviewed it for opioid withdrawal, chronic insomnia and narcolepsy, and a voting member who had backed the other peptides voted against it, citing potential downstream harm.

How Goodmorrow handles it

For sleep, your clinician starts with what's driving the problem. If epitalon becomes lawful, it's the peptide we'd look at first.

Questions people ask

Why was DSIP rejected when the others passed?

The vote was 6 in favor and 7 against. One pharmacist who supported the other peptides switched, citing concern about downstream consequences.

Sources

  1. Secondary sourceFDA advisory panel narrowly rejects compounding of one peptide, backs two others STAT, July 24, 2026
  2. Secondary sourceBulk-list bound? PCAC backs majority of peptides in two-day public meeting McDermott Will & Schulte, July 28, 2026

Good days ahead.

Join the opening list for appointment updates.

Join the opening list